Sugi Predict

Sugi Predict / Compounds / SCHEMBL5243287

SCHEMBL5243287

SCHEMBL5243287

COC(=O)c1cc(CBr)on1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 1/20 0.51
▸ MAPT P10636 2/20 0.50
▸ TP53 P04637 1/20 0.50
▸ MAPK1 P28482 5/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ NOTUM Q6P988 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ STAT3 P40763 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ RAB9A P51151 5/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28069664 0.86 SMN1; SMN2 (0.50) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL18255998 0.84 MRGPRX4 (0.52) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL18973243 0.84 MRGPRX4 (0.52) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL892010 0.83 CYP1A2 (0.46) MAPTTP53HSD17B10SMN1; SMN2CYP1A2
SCHEMBL9047880 0.82 MRGPRX4 (0.58) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL10644274 0.82 MRGPRX4 (0.58) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL10644438 0.82 MRGPRX4 (0.55) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL8145313 0.82 MRGPRX4 (0.51) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL10641694 0.82 MRGPRX4 (0.51) MRGPRX4MAPTTP53MAPK1HSD17B10
SCHEMBL4211979 0.81 MRGPRX4 (0.48) MRGPRX4MAPTTP53MAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663630-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR LG Chem, Ltd. (KR) 2025-12-17 — — EP disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 — — CN disclosed
WO-2024201308-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR 주식회사 엘지화학 2024-10-03 — — WO disclosed
CN-117736192-A PI3K/HDAC dual inhibitor and application thereof 安徽中医药大学 2024-03-22 — — CN disclosed
US-RE49128-E1 Hydroxyl purine compounds and applications thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2022-07-12 — — US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
CN-111848629-B mTOR/HDAC dual inhibitor and application thereof 安徽中医药大学 2021-06-11 — — CN disclosed
US-20060063930-A1 Compositions and methods comprising proteinase activated receptor antagonists ENTREMED, INC. 2006-03-23 — — US disclosed
WO-2006023844-A2 COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS ENTREMED, INC. (US) 2006-03-02 — — WO disclosed
EP-0555068-B1 Oxime derivatives as 5-lipoxygenase inhibitors ZENECA LTD (GB) 1996-04-10 — — EP disclosed
US-5482966-A LIPOXYGENASE ENZYME INHIBITORS AS ANTIINFLAMMATORY AGENTS ZENECA LIMITED (GB) 1996-01-09 — — US disclosed
US-5332757-A Enzyme inhibitors ZENECA LIMITED (GB) 1994-07-26 — — US disclosed
EP-0555068-A1 Oxime derivatives as 5-lipoxygenase inhibitors ZENECA LIMITED (GB) 1993-08-11 — — EP disclosed
EP-0123418-B1 4-HYDROXY-N-(5((SUBSTITUTED HETERO) METHYL)-3-ISOXAZOLYL-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE,1,1-DIOXIDE AND 4-HYDROXY-2-ALKYL-N-(5-((SUBSTITUTED HETERO) METHYL)-3-ISOXAZOLYL)2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE,1,1-DIOXIDE WARNER-LAMBERT COMPANY (US) 1988-01-20 — — EP disclosed
US-4581458-A 5-substituted-3-aminoisoxazole compounds WARNER-LAMBERT COMPANY (US) 1986-04-08 — — US disclosed
US-4489077-A 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides WARNER-LAMBERT COMPANY (US) 1984-12-18 — — US disclosed
EP-0123418-A1 4-Hydroxy-N-(5((substituted hetero) methyl)-3-isoxazolyl-2H-1,2-benzothiazine-3-carboxamide,1,1-dioxide and 4-hydroxy-2-alkyl-N-(5-((substituted hetero) methyl)-3-isoxazolyl)2H-1,2-benzothiazine-3-carboxamide,1,1-dioxide WARNER-LAMBERT COMPANY (US) 1984-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063930-A1 Compositions and methods comprising proteinase activated receptor antagonists F2RL1, PLAUR, F2R MRGPRX4 229/4885MAPT 4266/4885TP53 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.